
Allergan.Inc Patents

Matching "Allergan.Inc" by Owner.

IPMonitor
Patents

Contents

Alerts	3
"Allergan.Inc"	3
Terms and Conditions	21
General	21
Disclaimer of warranty and limitation of liability	21
Copyright	21
Arbitration	21

Alerts

"Allergan.Inc"

More than 500 results matching "'Allergan.Inc'" by Owner.

Number	Title	Owner
2001297521	Co-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists	Allergan, Inc.
2002303504	Compositions including vitamin-based surfactants ad methods for using same	ALLERGAN, INC.
2002305416	3, 7 or 3 and 7 thia or oxa prostanoid acid derivatives as agents for lowering intraocular pressure	Allergan, Inc.
2002307096	Methods of screening and using inhibitors of angiogenesis	ALLERGAN, INC.
2002308544	Disinfecting and solubilizing steroid compositions	Allergan, Inc.
2002312221	Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same	Allergan, Inc.
2002314975	CYCLOPENTANE HEPTAN (ENE) ACYL SULFONAMIDE, 2-ALKYL OR 2-ARYLALKYL, OR 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS	ALLERGAN, INC.
2002318324	Use of antimicrobial peptides as preservatives in ophthalmic preparations including solutions emulsions and suspensions	Allergan, Inc.
2002317523	Vaccine for Clostridium Botulinum Neurotoxin	Allergan, Inc. ; Allergan Botox Limited
2002316081	Prostanoid acid derivatives as agents for lowering intraocular pressure	Allergan, Inc.
2002318248	Rotational molding of medical articles	Allergan, Inc.
2002322694	FLIP TOP PIERCING TIP CAP	ALLERGAN, INC.
2002229075	Agents and methods for treating pain	Allergan, Inc.
2002329859	FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TOXINS	ALLERGAN, INC.
2002331876	BENZOFURAN, INDOLE OR BENZOTHIOPHENE 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS	ALLERGAN, INC.
2002336603	3-(HETEROARYLAMINO)METHYLEN E-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS	ALLERGAN, INC.
2002337663	METHODS OF DETERMINING THE EFFECTS OF TOXINS	ALLERGAN, INC.
2002340188	Targeting the reverse mode of the Na ⁺ /Ca ²⁺ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy	Allergan, Inc.
2002341881	3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors	Allergan, Inc.
2002341883	3-(HETEROARYLAMINO)METHYLEN E-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS	ALLERGAN, INC.

Number	Title	Owner
2003200441	Compositions and methods for modulating neural sprouting	Allergan, Inc.
2002242203	(2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors	Allergan, Inc.
2002344785	Glaucoma treatments with reduced hyperpigmentation	ALLERGAN, INC.
2002348424	Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain	Allergan, Inc.
2002349268	Medicine for preventing and treating bromidrosis	Allergan, Inc.
2002254265	Imidazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors	Allergan, Inc.
2002360613	Pharmaceutical conjugates with enhanced pharmacokinetic characteristics	Allergan, Inc.
2002361671	OPHTHALMIC COMPOSITIONS COMPRISING TWO DIFFERENT POLYANIONIC COMPONENTS FOR LUBRICATING EYES AND METHODS FOR MAKING AND USING SAME	ALLERGAN, INC.
2002256147	LACTAM COMPOUNDS FOR PENETRATION ENHANCEMENT	ALLERGAN, INC.
2002258847	Alpha-2-adrenergic agonist/fatty acid compositions	Allergan, Inc.
2002259030	METHODS OF TREATING HYPERLIPIDEMIA	ALLERGAN INC.
2002256471	Compositions having enhanced pharmacokinetic characteristics	Allergan, Inc.
2002259188	RECOMBINANT SIMIAN GPR3 RECEPTOR	ALLERGAN, INC.
2002259210	3, 7 or 3 and 7 thia or oxa prostanoid derivatives as agents for lowering intraocular pressure	Allergan, Inc.
2002362992	METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY	ALLERGAN, INC.
2003207843	Method of enhancing hair growth	Allergan, Inc.
2003210699	Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same	Allergan, Inc.
2002363319	Omega-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS	ALLERGAN, INC.
2003213610	Preparation of prostamides	Allergan, Inc.
2003213848	Substituted chroman derivatives having cytochrome P450RAI inhibitory activity	Allergan, Inc.
2003215337	Methods of extending corneal graft survival	Allergan, Inc.
2003220511	Use of botulinum toxin for treating cardiovascular diseases	Allergan, Inc.
2003228427	(3Z) - 3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors	Allergan, Inc.
2002366094	COMPOSITION AND METHOD FOR MODULATING BAR/FXR RECEPTOR ACTIVITY	ALLERGAN, INC.
2003228480	Combination of brimonidine and timolol for topical ophthalmic use	Allergan, Inc.

Number	Title	Owner
2003230720	DIHYDROBENZOFURAN AND DIHYDROBENZOTHIOPHENE 2,4-PENTAIDENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS	ALLERGAN, INC.
2003230969	COMPOSITIONS FOR TREATING HYPEREMIA	ALLERGAN, INC.
2003231142	Compositions and their uses for alleviating pain	Allergan, Inc.
2003231188	8-Azaprostaglandin analogs as agents for lowering intraocular pressure	ALLERGAN, INC.
2003221922	Intracranial treatment of neuropsychiatric disorders by clostridial neurotoxins such as botulinum toxin	Allergan, Inc
2003224654	PHOTODYNAMIC THERAPY FOR PRE-MELANOMAS	ALLERGAN, INC.
2003224657	METHOD FOR DETERMINING EFFECT OF A CLOSTRIDIAL TOXIN UPON A MUSCLE	ALLERGAN, INC.
2003225130	METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN	ALLERGAN, INC.
2003225549	Methods for treating mammary gland disorders	Allergan, Inc.
2003243770	Botulinum toxins for treating priapism	Allergan, Inc.
2003245286	4-SUBSTITUTED IMIDAZOLE2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS	ALLERGAN, INC.
2003245593	Two-way slit valve	Allergan, Inc.
2003247976	OPHTHALMIC COMPOSITIONS CONTAINING LORATADINE	ALLERGAN, INC.
2003255236	TRICYCLO(6.2.2)DODECA-2(7),3,5-TRIE N4-CARBONYLAMINO)-DERIVATIVES HAVING RAR-ALPHARECEPTOR SELECTIVE BIOLOGICAL ACTIVITY	ALLERGAN, INC.
2003256370	Use of dantrolene, a ryanodine antagonist, in treating neural injury	Allergan Inc.
2003261352	THE 9, 11-CYCLOENDOPEROXIDE PRO-DRUGS OF PROSTAGLANDIN ANALOGUES FOR TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA	ALLERGAN, INC.
2001251546	Method for treating pain by peripheral administration of a neurotoxin	Allergan, Inc
2010321831	7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof	Allergan, Inc.
2003262871	Fatigue-resistant gastric banding device	Allergan, Inc.
2003267987	Transdermal botulinum toxin compositions	Allergan, Inc
2010353292	Modified Clostridial toxins comprising an integrated protease cleavage sitebinding domain	Allergan, Inc.
2003272575	Methods and apparatus for delivery of ocular implants	Allergan, Inc.
2012202870	Piperidinyl prostaglandin analogs as ocular hypotensive agents	Allergan, Inc.
2001273166	Methods for treating inflammation-mediated conditions of the eye	Allergan, Inc.
2002236495	Intraocular implants for preventing transplant rejection in the eye	Allergan, Inc.

Number	Title	Owner
2003279282	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER	ALLERGAN, INC.
2003279874	METHOD OF USING (2-IMIDAZOLIN-2-YLAMINO) QINOXALINES IN THE TREATMENT OF DEMENTIA AND PARKINSONS	ALLERGAN, INC.
2002368109	Fret protease assays for clostridial toxins	Allergan, Inc.
2003282758	ALPHA 2B OR 2B/2C ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATION	ALLERGAN, INC.
2003282790	Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins	Allergan, Inc.
2003286901	Oral formulation of botulinum toxin and use thereof for treating peptic ulcers and gastroesophageal reflux disease	Allergan, Inc.
2003287155	BOTULINUM TOXIN DENTAL THERAPIES AND PROCEDURES	ALLERGAN, INC.
2003287463	Botulinum toxin formulations for oral administration	Allergan, Inc.
2003295658	KINASE INHIBITORS THE TREATMENT OF DISEASE	ALLERGAN, INC
2003296509	EVOLVED CLOSTRIDIAL TOXINS WITH ALTERED PROTEASE SPECIFICITY	ALLERGAN, INC.
2003298747	Active agent delivery method	ALLERGAN, INC.
2001238313	Method for treating ocular pain	Allergan, Inc.
2003301673	METHODS OF TREATMENT DURING VASCULAR PROCEDURES	ALLERGAN, INC.
2001265142	Method for treating a movement disorder	Allergan, Inc.
2005200248	Method for treating dystonia with botulinum toxin type B	Allergan, Inc.
2005200251	Method for treating pain associated with a muscle disorder	Allergan, Inc.
2001286991	Methods for treating muscle injuries	Allergan, Inc.
2010324988	Novel compounds as receptor modulators with therapeutic utility	Allergan, Inc.
2004204744	Biodegradable ocular implant	Allergan, Inc.
2005203171	Botulinum toxin pharmaceutical compositions	Allergan, Inc.
2010324983	Novel compounds as receptor modulators with therapeutic utility	Allergan, Inc.
2001273269	Compositions containing alpha2-adrenergic agonist components	Allergan, Inc.
2001273268	Compositions containing therapeutically active components having enhanced solubility	Allergan, Inc.
2001284972	Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents	Allergan, Inc.
2004211936	10,10-dialkyl prostanoid acid derivatives as agents for lowering intraocular pressure	Allergan, Inc.
2004218467	Clostridial neurotoxins for treating uterine disorders	Allergan, Inc.
2001253383	Methods and compositions for modulating alpha adrenergic receptor activity	Allergan, Inc.

Number	Title	Owner
2005220199	Compositions containing alpha2-adrenergic agonist components	Allergan, Inc.
2004226466	Preserved ophthalmic compositions	Allergan, Inc.
2004231966	Controlled volume injection/aspiration device	Allergan, Inc.
2004233821	Botulinum neurotoxin for treating tics and obsessive compulsive behaviors	Allergan, Inc.
2004235743	Methods for treating sinus headache	Allergan, Inc.
2005234735	Compositions containing therapeutically active components having enhanced solubility	Allergan, Inc.
2004249132	Clostridial toxins for treating eye disorders	Allergan, Inc.
2004245490	8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents	Allergan, Inc.
2004245492	3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure	Allergan, Inc.
2004245122	Piperidinyl prostaglandin E analogs	Allergan, Inc.
2005246995	Methods for treating inflammation-mediated conditions of the eye	Allergan, Inc.
2004249238	Needless injectors	Allergan, Inc.
2004251708	Use of a clostridial toxin to reduce appetite	Allergan, Inc.
2001236665	Ocular hypotensive lipids	Allergan, Inc.
2004249151	Memantine oral dosage forms	Allergan, Inc.
2004253500	Use of brimonidine for preventing and reducing the severity of stress-associated conditions	Allergan, Inc.
2004260645	Delivery of a drug via subconjunctival or periocular delivery of a prodrug in a polymeric microparticle	Allergan, Inc.
2004264401	Process for preparing isomerically pure prodrugs of proton pump inhibitors	Allergan, Inc.
2001253384	Methods and compositions for modulating alpha adrenergic receptor activity	Allergan, Inc.
2001285196	2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)ic acid as therapeutic agents	Allergan, Inc.
2004258884	Titration/compliance pack	Allergan, Inc.
2004261286	Methods of therapeutic treatment using amounts of retinoid components	Allergan, Inc.
2004261301	Methods of therapeutic treatment using amounts of retinoid components	Allergan, Inc.
2004263149	Compositions for delivery of therapeutics into the eyes and methods for making and using same	Allergan, Inc.
2004257770	Device to assist hyperhydrosis therapy	Allergan, Inc.
2004263156	Method for treating cachexia with retinoid ligands	Allergan, Inc.
2004270155	Cyclohexyl prostaglandin analogs as EP4-receptor agonists	Allergan, Inc.
2004279336	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions	Allergan, Inc.
2004272524	Cyclopentane heptan(ene)ic acid, 2-thiocarbamoyloxy and carbamoyloxy compounds as therapeutic agents	Allergan, Inc.
2004279332	Nonsedating alpha-2 agonist 1- (2, 3-dimethyl-phenyl) -ethyl-1, 3-dihydro-imizadole-2-thione	Allergan, Inc.
2004279333	Methods for identifying improved, nonsedating alpha-2 agonists	Allergan, Inc.

Number	Title	Owner
2004281641	Implantable device fastening system and methods of use	Allergan, Inc.
2006201271	Intraocular implants for preventing transplant rejection in the eye	Allergan, Inc.
2004268633	Using selective antagonists of persistent sodium current to treat neurological disorders and pain	Allergan, Inc.
2004280450	Animal product free media and processes for obtaining a botulinum toxin	Allergan, Inc.
2004279378	Methods and compositions for the oral administration of prodrugs of proton pump inhibitors	Allergan, Inc.
2006201701	Methods and compositions for treatment of ocular neovascularization and neural injury	Allergan, Inc.
2004283091	Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia	Allergan, Inc.
2004316860	Botulinum toxin treatments of neurological and neuropsychiatric disorders	Allergan, Inc.
2004289300	Compositions and methods for treating a posterior segment of an eye	Allergan, Inc.
2004289685	Process for the synthesis of imidazoles	Allergan, Inc.
2004291507	Novel prostamides for the treatment of glaucoma and related diseases	Allergan, Inc.
2004291152	Rescue agents for treating botulinum toxin intoxications	Allergan, Inc.
2004296748	Prevention and/or reduction of photoreceptor degeneration with retinoids	Allergan, Inc.
2004296870	Botulinum toxin therapy for skin disorders	Allergan, Inc.
2004315599	Lipid rafts and Clostridial toxins	Allergan, Inc.
2001290692	Interheteroaryl 7-oxabicyclic (2.2.1)heptane oxazoles as prostaglandin F2alpha antagonists	Allergan, Inc.
2001255488	Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies	Allergan, Inc. ; The Trustees of the University of Pennsylvania
2005204365	Compositions comprising memantine and polyanionic polymers for administration to the eye	Allergan, Inc.
2005204375	Methods for treating vascular disorders	Allergan, Inc.
2005205597	Chimera botulinum toxin type E	Allergan, Inc.
2005209201	Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid	Allergan, Inc.
2005209209	Piperidinyl prostaglandin E analogs	Allergan, Inc.
2005209251	Implantable device fastening system and methods of use	Allergan, Inc.
2002239329	A high-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels	Allergan, Inc.
2002219850	Modified clostridial neurotoxins with altered biological persistence	Allergan Inc.
2001292595	Interphenylene 7-oxabicyclic(2.2.1)heptane oxazoles as prostaglandin F2a antagonists	Allergan, Inc.
2005216862	Compositions comprising prodrugs of proton pump inhibitors	Allergan, Inc.

Number	Title	Owner
2001280703	Leucine-based motif and clostridial neurotoxins	Allergan, Inc.
2005216863	Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors	Allergan, Inc.
2001286471	Compounds having activity as inhibitors of cytochrome P450RAI	Allergan, Inc.
2005216547	Botulinum toxin screening assays	Allergan, Inc.
2005208721	Releasably-securable one-piece adjustable gastric band	Allergan, Inc.
2006213932	Tyrosine-based motif and clostridial neurotoxins	Allergan, Inc.
2005327457	Media for clostridium bacterium and processes for obtaining a clostridial toxin	Allergan, Inc.
2005327458	Animal product free system and process for purifying a botulinum toxin	Allergan, Inc.
2004317849	Apparatus and method for volume adjustment of intragastric balloons	Allergan, Inc.
2005216887	Medicaments and methods for treating headache	Allergan, Inc.
2006225278	Combination of brimonidine and timolol for topical ophthalmic use	Allergan, Inc.
2005231360	Pressure sore treatment	Allergan, Inc.
2005222574	Methods and compositions for the treatment of conditions related to gastric acid secretion	Allergan, Inc.
2005237421	Aqueous solutions comprising pred- nislone and cyclodextrin derivative.	Allergan, Inc.
2005243727	Multi-site injection system	Allergan, Inc.
2006233216	Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies	Allergan, Inc. ; The Trustees of the University of Pennsylvania
2005244195	Biodegradable ocular implants with long-term release characteristics	Allergan, Inc.
2005290334	Stabilized biodegradable neurotoxin implants	Allergan, Inc.
2005240078	Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing	Allergan, Inc.
2005240081	Anti-excitotoxic sustained release intraocular implants and related methods	Allergan, Inc.
2005240093	Biodegradable intravitreal tyrosine kinase inhibitors implants	Allergan, Inc.
2005244202	Macromolecule-containing sustained release intraocular implants and related methods	Allergan, Inc.
2005244211	Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies	Allergan, Inc.
2005244213	Intravitreal implants in conjunction with photodynamic therapy to improve vision	Allergan, Inc.
2005240092	Steroid intraocular implants having an extended sustained release for a period of greater than two months	Allergan, Inc.
2005244149	Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision	Allergan, Inc.
2005244203	Biodegradable intraocular implants containing prostamides	Allergan, Inc.

Number	Title	Owner
2005244216	An estradiol derivative or an estratopone derivative containing sustained release intraocular implant as well as related methods of manufacturing	Allergan, Inc.
2005244780	Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer	Allergan, Inc.
2006249248	Pharmaceutical compositions having activity as inhibitors of cytochrome P450RAI	Allergan, Inc.
2005252171	Piperidinyl prostaglandin analogs as ocular hypotensive agents	Allergan, Inc.
2005253931	Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide	Allergan, Inc.
2005262652	Abnormal Cannabidiols for lowering intraocular pressure	Allergan, Inc.
2006252170	Method for treating pain associated with a muscle disorder	Allergan, Inc.
2006252171	Method for treating pain associated with a muscle disorder	Allergan, Inc.
2002230567	Compositions for treatment of ocular neovascularization and neural injury	Allergan, Inc.
2007200122	Methods for treating inflammation-mediated conditions of the eye II	Allergan, Inc.
2007200658	Use of botulinum toxin for treating cardiovascular diseases	Allergan, Inc.
2005270230	Prostaglandin analogs	Allergan, Inc.
2002228684	Neurotoxins with enhanced target specificity	Allergan, Inc.
2005267603	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions	Allergan, Inc.
2005270229	Prostaglandin analogs	Allergan, Inc.
2005271700	Ophthalmic compositions and methods for treating ophthalmic conditions	Allergan, Inc.
2005269293	Methods of treating ophthalmic conditions	Allergan, Inc.
2005271372	Optimizing expression of active botulinum toxin type A	Allergan, Inc.
2005272796	GFP-SNAP25 fluorescence release assay for botulinum toxin protease activity	Allergan, Inc.
2005273992	Container system	Allergan, Inc.
2005278015	Needleless microprotrusion elastoplast system	Allergan, Inc.
2005290008	4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists	Allergan, Inc.
2005290240	Ocular implant made by a double extrusion process	Allergan, Inc.
2005289998	4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists	Allergan, Inc.
2005310267	Toxin compounds with enhanced membrane translocation characteristics	Allergan, Inc.
2007200821	Hypotensive lipid and timolol compositions and methods of using same	Allergan, Inc.
2005279741	Degradable clostridial toxins	Allergan, Inc.
2005280259	Compositions containing alpha2-adrenergic agonist components	Allergan, Inc.

Number	Title	Owner
2005280574	Methods for treating cancer	Allergan, Inc.
2005282409	Use of a botulinum toxin for treating a buttock deformity	Allergan, Inc.
2005282967	Stretch mark treatment with botulinum toxic	Allergan, Inc.
2005287262	Lanthanide-based substrates and methods for determining clostridial toxin activity	Allergan, Inc.
2005290013	Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thione s acting as specific or selective alpha2 adrenergic agonists and methods for using the same	Allergan, Inc.
2005290075	4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists	Allergan, Inc.
2005292595	Cosmetic neurotoxin compositions comprising a botulinum toxin component and methods	Allergan, Inc.
2005333632	Fluorescence polarization assays for determining clostridial toxin activity	Allergan, Inc.
2005299473	Therapeutic and delivery methods of prostaglandin EP4 agonists	Allergan, Inc.
2005304764	Substituted pyrrolidone compounds as EP4 agonists	Allergan, Inc.
2005306656	2,3,4-substituted cyclopentanones as therapeutic agents	Allergan, Inc.
2005306721	Ophthalmic compositions and methods for treating eyes	Allergan, Inc.
2007202480	Method for treating pain associated with a muscle disorder	Allergan, Inc.
2007202481	Method for treating pain associated with a muscle disorder	Allergan, Inc.
2007202482	Method for treating pain associated with a muscle disorder	Allergan, Inc.
2007202484	Method for treating pain associated with a muscle disorder	Allergan, Inc.
2007202485	Method for treating pain associated with a muscle disorder	Allergan, Inc.
2005309605	2,3,4-substituted-cyclopentanones as therapeutic agents	Allergan, Inc.
2005309622	Treatment of inflammatory bowel disease	Allergan, Inc.
2005311086	Fusion proteins	Health Protection Agency ; Allergan, Inc.
2005311098	Non-cytotoxic protein conjugates	Health Protection Agency ; Allergan, Inc.
2007202599	Compositions containing alpha2-adrenergic agonist components	Allergan, Inc.
2005314000	12-aryl prostaglandin analogs	Allergan, Inc.
2007202972	A diary/planner for breast surgery preparation and method	Allergan, Inc.
2006205029	Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions	Allergan, Inc.
2006209197	Use of 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics	Allergan, Inc.
2006209207	3-heterocycl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity	Allergan, Inc.

Number	Title	Owner
2006209208	1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/ or immuno stimulant activity	Allergan, Inc.
2006209209	3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity	Allergan, Inc.
2007205721	Rotational molding of medical articles	Allergan Inc.
2005326660	Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions	Allergan, Inc.
2006218931	Microimplants for ocular administration	Allergan, Inc.
2006223514	Substituted gamma lactams as therapeutic agents	Allergan, Inc.
2006227693	Treatment of inflammatory bowel disease	Allergan, Inc.
2006227757	Enhanced bimatoprost ophthalmic solution	Allergan, Inc.
2006227816	Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems	Allergan, Inc.
2006244583	Substituted beta-lactams and their use in medicine	Allergan, Inc.
2006339490	Clostridial toxin activatable clostridial toxins	Allergan, Inc.
2006244083	Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates	Allergan Inc.
2006259728	Treatment of autoimmune disorders with a neurotoxin	Allergan, Inc.
2006266397	Alpha-2 adrenergic agonists for the treatment of pain	Allergan Inc.
2006268174	Kinase inhibitors	Allergan Inc.
2006268264	Cyclosporin compositions	Allergan Inc.
2006268265	Kinase inhibitors	Allergan Inc.
2006269301	3-spirocyclopropyl-2-oxindole kinase inhibitors	Allergan Inc.
2006275999	Improved botulinum toxin compositions	Allergan, Inc.
2006283208	Sulfonamides	Allergan, Inc.
2006283638	Botulinum toxin in treatment of clubfoot relapse	Allergan, Inc.
2006285177	EP2 receptor agonists for treating glaucoma	Allergan Inc.
2006295305	Compositions and methods for the intraocular transport of therapeutic agents	Allergan Inc.
2006299366	Non-protein stabilized clostridial toxin pharmaceutical compositions	Allergan, Inc.
2006304151	Assays of molecular or subcellular interactivity using depolarization after resonance energy transfer (DARET)	Allergan, Inc.
2006304416	Ocular therapy using Glucocorticoid Derivatives selectively penetrating posterior segment tissues	Allergan Inc.
2006225116	Modified Clostridial toxins with altered targeting capabilities for Clostridial toxin target cells	Allergan, Inc.
2006231470	Lipophilic dye-based FRET assays for Clostridial toxin activity	Allergan, Inc.
2001286478	Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome P450RAI	Allergan, Inc.
2006340711	Clostridial toxin activity assays	Allergan, Inc.

Number	Title	Owner
2010328555	Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof	Allergan, Inc.
2007231916	Ophthalmic compositions including oilin-water emulsions, and methods for making and using the same	Allergan, Inc.
2007254589	Methods and apparatus for delivery of ocular implants	Allergan, Inc.
2007254671	Combination of brimonidine and timolol for topical ophthalmic use	Allergan, Inc.
2006283619	Novel sulfonamides	Allergan, Inc.
2006287805	Method of treating glaucoma	Allergan, Inc.
2008201176	Botulinum toxin pharmaceutical compositions	Allergan, Inc.
2006304143	Prevention and treatment of drugassociated ocular side effects with a cyclosporin	Allergan, Inc.
2006306193	Variable cohesive gel form-stable breast implant	Allergan, Inc.
2008201932	Fret protease assays for clostridial toxins	Allergan, Inc.
2008201963	Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain	Allergan, Inc.
2006311942	Prostaglandins and analogues as agents for lowering intraocular pressure	Allergan, Inc.
2008202206	Methods of using ryanodine antagonists in treating neural injury	Allergan, Inc.
2008202358	Fatigue-resistant gastric banding device	Allergan, Inc.
2008237541	Use of the neurotoxic component of a botulinum toxin	Allergan, Inc.
2008202928	Fret protease assays for clostridial toxins	Allergan, Inc.
2006335371	Self-regulating gastric band	Allergan, Inc.
2007207631	The use of memantine and brimonidine to attenuate vitreoretinal vascular endothelial growth factor (VEGF) protein levels in animals	Allergan, Inc.
2008203212	Method of enhancing hair growth	Allergan, Inc.
2007210155	Biodegradable non-ophthalmic implants and related methods	Allergan, Inc.
2007293169	Compositions and methods for the treatment of ophthalmic disease	Allergan, Inc.
2008205427	Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors	Allergan, Inc.
2008207538	Using selective antagonists of persistent sodium current to treat neurological disorders and pain	Allergan, Inc.
2008207539	Using selective antagonists of persistent sodium current to treat neurological disorders and pain	Allergan, Inc.
2008207547	Using selective antagonists of persistent sodium current to treat neurological disorders and pain	Allergan, Inc.
2008207560	Using selective antagonists of persistent sodium current to treat neurological disorders and pain	Allergan, Inc.
2007214434	Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity	Allergan, Inc.
2008207629	Using selective antagonists of persistent sodium current to treat neurological disorders and pain	Allergan, Inc.

Number	Title	Owner
2008207631	Using selective antagonists of persistent sodium current to treat neurological disorders and pain	Allergan, Inc.
2008207633	Using selective antagonists of persistent sodium current to treat neurological disorders and pain	Allergan, Inc.
2008207634	Using selective antagonists of persistent sodium current to treat neurological disorders and pain	Allergan, Inc.
2007223057	Ocular therapy using sirtuin-activating agents	Allergan, Inc.
2007223361	Treatment with cyclosporin A	Allergan, Inc.
2007226657	Multivalent Clostridial toxins	Allergan, Inc.
2007226957	Substituted gamma lactams as prostaglandin EP2 agonists	Allergan, Inc.
2007233212	Therapeutic prostaglandin compounds for the treatment of glaucoma	Allergan, Inc.
2007233285	Prostaglandin EP4 agonists	Allergan, Inc.
2007235002	Compositions including relatively water insoluble/unwetttable drugs and methods for using same	Allergan, Inc.
2007238296	Brimonidine and timolol compositions	Allergan, Inc.
2007244978	Abnormal Cannabidiols as agents for lowering intraocular pressure	Allergan, Inc.
2007248119	12-aryl or heteroaryl prostaglandin analogs	Allergan, Inc.
2007248143	A sustained-release intraocular implant comprising a vasoactive agent	Allergan, Inc.
2007248180	Cyclopentane-derivatives and their use as ocular hypotensive agents	Allergan, Inc.
2007248192	Therapeutic cyclopentane derivatives	Allergan, Inc.
2007249443	Isothiazolidines useful in the treatment of ocular hypertensive conditions	Allergan, Inc.
2007253949	Therapeutic fluoroethyl ureas	Allergan, Inc.
2007266489	Locator system for implanted access port with RFID tag	Allergan, Inc.
2007267620	Therapeutic pyrrolidine compounds	Allergan, Inc.
2007267653	Therapeutic cyclopentane derivatives	Allergan, Inc.
2007256774	Eyelash applicator and method	Allergan, Inc.
2007256920	Use of a botulinum toxin for treating a urethral stricture	Allergan, Inc.
2007257768	Substituted gamma lactams as therapeutic agents	Allergan, Inc.
2007257825	Intragastric balloon retrieval mechanisms	Allergan, Inc.
2007261034	Therapeutic compounds	Allergan, Inc.
2007260917	Self-regulating gastric band with pressure data processing	Allergan, Inc.
2007281875	Steroid-containing sustained release intraocular implants and related methods	Allergan, Inc.
2007272515	Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells	Allergan, Inc.
2007272517	Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for nonclostridial toxin target cells	Allergan, Inc.
2007272617	Cyclopentane derivatives as antiglaucoma agents	Allergan, Inc.

Number	Title	Owner
2007272683	Substituted cyclopentane derivatives as therapeutic agents	Allergan, Inc.
2007272730	Cyclopentane derivatives as antiglaucoma agents	Allergan, Inc.
2007347781	Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity	Allergan, Inc.
2007276815	Cyclosporin compositions	Allergan, Inc.
2007284085	Therapeutic amides and related compounds	Allergan, Inc.
2007286135	N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives as prostaglandine receptor inhibitors	Allergan, Inc.
2007286177	Therapeutic lactams	Allergan, Inc.
2007286756	Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds	Allergan, Inc.
2007292347	Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist and/or antagonist biological activity	Allergan, Inc.
2007292436	Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity	Allergan, Inc.
2007303546	Apparatus and method for intragastric balloon with in situ adjustment means	Allergan, Inc.
2007348955	Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures	Allergan, Inc.
2007319151	Sulfoximines as kinase inhibitors	Allergan, Inc.
2007323857	Prostaglandin prodrugs as ocular hypotensive agents	Allergan, Inc.
2009202136	Botulinum toxin screening assays	Allergan, Inc.
2007329723	Intraocular drug delivery systems	Allergan, Inc.
2007337139	Processes for making cyclic lipid implants for intraocular use	Allergan, Inc.
2007334038	Methods and compositions for treating gastrointestinal disorders	Allergan, Inc.
2007337089	Alpha-2B receptor agonist and anticonvulsant compositions for treating chronic pain	Allergan, Inc.
2007337097	Alpha-2B adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain	Allergan, Inc.
2008206495	6-substituted indole-3-carboxylic acid amide compounds having Sphingosine1-Phosphate (S1P) receptor antagonist biological activity	Allergan, Inc.
2009202969	Ketorolac tromethamine compositions for treating or preventing ocular pain	Allergan, Inc.
2008207991	Thiophene derivatives useful as ocular hypotensive agents	Allergan, Inc.
2008208032	Substituted arylcyclopentenes as therapeutic agents	Allergan, Inc.
2008208042	Substituted arylcyclopentenes as therapeutic agents	Allergan, Inc.
2008210559	Substituted gamma lactams as therapeutic agents	Allergan, Inc.
2008211083	Novel biomaterials for ocular drug delivery and a method for making and using same	Allergan, Inc.
2008216499	Gamma-lactams for the treatment of glaucoma or elevated intraocular pressure	Allergan, Inc.

Number	Title	Owner
2012203398	Ophthalmic compositions and methods for treating eyes	Allergan, Inc.
2012203366	Modified Clostridial toxins with altered targeting capabilities for Clostridial toxin target cells	Allergan, Inc.
2008222890	Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds	Allergan, Inc.
2009222473	Compositions and methods for treating a posterior segment of an eye	Allergan, Inc.
2009222590	(3Z) - 3-(hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors	Allergan, Inc.
2009222589	Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins	Allergan, Inc.
2008239896	Remote deflation of intragastric balloon	Allergan, Inc.
2008245503	High viscosity macromolecular compositions for treating ocular conditions	Allergan, Inc.
2008247680	Use of cyclosporines in the treatment of patients with intraocular lenses	Allergan, Inc.
2009238370	Alpha 2B or 2B/2C adrenoceptor agonists for the treatment of neurodegeneration	Allergan, Inc.
2008251324	((Phenyl)imidazolyl)methylheteroaryl compounds	Allergan Inc.
2008254717	Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure	Allergan, Inc.
2008256819	Cross-linked collagen and uses thereof	Allergan, Inc.
2008256864	Coated hyaluronic acid particles	Allergan, Inc.
2008256879	Hydraulic gastric band with collapsible reservoir	Allergan, Inc.
2008256926	((Bicyclicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists	Allergan, Inc.
2008256928	Therapeutic ((phenyl)imidazolyl)methylquinoliny compounds	Allergan, Inc.
2008260101	Biological tissue growth through induced tensile stress	Allergan, Inc. ; Baroni, G. ; Rigotti, G.
2008269965	Therapeutic substituted cyclopentanes for reducing intraocular pressure	Allergan, Inc.
2008276278	Methods for treating anxiety	Allergan, Inc.
2008282479	All-barrier elastomeric gel-filled breast prosthesis	Allergan, Inc.
2008282541	Tunably crosslinked hyaluronic acid compositions	Allergan, Inc.
2010201167	4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2B and alpha-2C adrenergic receptors	Allergan, Inc.
2010200703	Clostridial neurotoxins for treating uterine disorders	Allergan, Inc.
2010200730	Method of using (2-imidazolin-2-ylamino) quinoxalines in the treatment of dementia and parkinsons	Allergan, Inc.
2008286818	Adrenergic compounds	Allergan, Inc.
2008286823	Therapeutic compounds	Allergan, Inc.
2008286824	Heterocyclyl substituted fused carbocycles useful in the treatment of conditions such as glaucoma and pain	Allergan, Inc.

Number	Title	Owner
2008288897	Pyrrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity	Allergan, Inc.
2008288898	Therapeutic quinoline and naphthalene derivatives	Allergan, Inc.
2010200935	Steroid intraocular implants having an extended sustained release for a period of greater than two months	Allergan, Inc.
2008302309	Steroid containing ophthalmic drug delivery systems	Allergan, Inc.
2008349774	Cyclosporin compositions	Allergan, Inc.
2010201226	8-azaprostaglandin analogs as agents for lowering intraocular pressure	Allergan, Inc.
2008304657	Indole compounds bearing aryl or heteroaryl groups having sphingosine 1-phosphate (S1P) receptor biological activity	Allergan, Inc.
2008310957	Crossed-linked hyaluronic acid and collagen and uses thereof	Allergan, Inc.
2010201790	Implantable device fastening system and methods of use	Allergan, Inc.
2010201793	Implantable device fastening system and methods of use	Allergan, Inc.
2008316988	Methods of treating chronic neurogenic inflammation using modified clostridial toxins	Allergan, Inc.
2008316989	Methods of treating urogenital-neurological disorders using modified clostridial toxins	Allergan, Inc.
2008317024	Pressure sensing intragastric balloon	Allergan, Inc.
2008317107	Therapeutic substituted lactams	Allergan, Inc.
2008324793	Substituted cyclopentanes having prostaglandin activity	Allergan, Inc.
2010202098	Fatigue-resistant gastric banding device	Allergan, Inc.
2008331597	Substituted cyclopentanes having prostaglandin activity	Allergan, Inc.
2008331602	Polysaccharide gel formulation	Allergan, Inc.
2008331491	Polysaccharide gel compositions and methods for sustained delivery of drugs	Allergan, Inc.
2008335446	Form stable breast implant sizer and method of use	Allergan, Inc.
2010202674	Hypotensive lipid and timolol compositions and methods of using same	Allergan, Inc.
2008338505	Breast reconstruction or augmentation using computer-modeled deposition of processed adipose tissue	Allergan, Inc.
2009204358	Substituted aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors	Allergan, Inc.
2008347006	6-substituted indole-3-carboxylic acid amide compounds having sphingosine 1-phosphate (S1P) receptor antagonist biological activity	Allergan, Inc.
2009205472	Selective subtype alpha 2 adrenergic agents and methods for use thereof	Allergan, Inc.
2012203056	Fusion proteins	Health Protection Agency ; Allergan Inc.
2009205473	Oxazolidine and thiazolidine selective subtype alpha 2 adrenergic agents and methods for use thereof	Allergan, Inc.

Number	Title	Owner
2009205477	Beta-lactams for the treatment of glaucoma, ocular hypertension, baldness and hair loss	Allergan, Inc.
2009205478	Therapeutic compounds	Allergan, Inc.
2009206137	Selective subtype alpha 2 adrenergic agents and methods for use thereof	Allergan, Inc.
2009205539	Substitutedaryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors	Allergan, Inc.
2012203055	Fusion proteins	Health Protection Agency ; Allergan Inc.
2009206587	Hydrazines in glaucoma therapy	Allergan, Inc.
2009209330	Substituted gamma lactams as therapeutic agents	Allergan, Inc.
2009212519	3-(4-fluorophenyl)-3-hydroxy-2-amino-p ropionic acid amides and related compounds having analgesic activity	Allergan, Inc.
2009212570	Substituted cyclopentanes having prostaglandin activity	Allergan, Inc.
2008351422	Dapsone to treat rosacea	Allergan, Inc.
2009215664	Sustained release poloxamer containing pharmaceutical compositions	Allergan, Inc.
2010214763	Two-way slit valve	Allergan, Inc.
2010219293	Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid	Allergan, Inc.
2009222016	Ketorolac tromethamine compositions for treating or preventing ocular pain	Allergan, Inc.
2009223435	Therapeutic compounds	Allergan, Inc.
2009223161	Immuno-based botulinum toxin serotype A activity assays	Allergan, Inc.
2010224394	Anti-excitotoxic sustained release intraocular implants and related methods	Allergan, Inc.
2009225693	Therapeutic compounds	Allergan, Inc.
2009225706	Therapeutic substituted cyclopentanes	Allergan, Inc.
2009225747	S1P3 receptor inhibitors for treating inflammation	Allergan, Inc.
2009228449	Selective subtype alpha 2 adrenergic agents and methods for use thereof	Allergan, Inc.
2009231786	Suture line administration technique using botulinum toxins	Allergan, Inc.
2010227111	Method of enhancing hair growth	Allergan, Inc.
2010235967	Ocular implant made by a double extrusion process	Allergan, Inc.
2009236055	Implantable access port device and attachment system	Allergan, Inc.
2009239371	Thiophene derivatives useful as ocular hypotensive agents	Allergan, Inc.
2009239372	Substituted gamma lactams as therapeutic agents	Allergan, Inc.
2009239377	Substituted arylcyclopentenes as therapeutic agents	Allergan, Inc.
2009239381	Substituted gamma lactams as therapeutic agents	Allergan, Inc.
2009240634	Remotely adjustable gastric banding system	Allergan, Inc.
2009239369	Substituted arylcyclopentenes as prostaglandin EP2 agonists	Allergan, Inc.
2009241578	Flush patch for elastomeric implant shell	Allergan, Inc.

Number	Title	Owner
2010241513	Use of brimonidine for preventing and reducing the severity of stress-associated conditions	Allergan, Inc.
2009236356	Combination therapy for glaucoma	Allergan, Inc.
2009244536	Alpha2B and alpha2C agonists	Allergan, Inc.
2009244325	Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds	Allergan, Inc.
2009244513	Therapeutic cyclopentane derivatives	Allergan, Inc.
2009244535	Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives	Allergan, Inc.
2009244538	Therapeutically useful substituted 1, 7-diphenyl-1, 2, 3, 5, 6, 7-hexahydropyrido [3, 2, 1-I J] quinoline compounds	Allergan, Inc.
2009244539	Therapeutic substituted hydantoin, and related compounds	Allergan, Inc.
2009244541	Therapeutic compounds	Allergan, Inc.
2009246572	Selective subtype alpha 2 adrenergic agents and methods for use thereof	Allergan, Inc.
2009246573	Therapeutic substituted cyclopentanes	Allergan, Inc.
2009246600	Naphthylmethylimidizoles for the treatment of stress urinary incontinence	Allergan, Inc.
2009246601	Quinolynylmethylimidizoles as therapeutic agents	Allergan, Inc.
2009249246	Bicyclic compounds having activity at the CXCR4 receptor	Allergan, Inc.
2009249386	Therapeutic prostaglandin compounds used as ocular hypotensive agents	Allergan, Inc.
2009249388	Therapeutic lactams	Allergan, Inc.
2009251474	Prostaglandin produgs as hypotensive agents	Allergan, Inc.
2009257591	Implantable pump system	Allergan, Inc.
2009262896	Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form	Allergan, Inc.
2010249170	Needleless injectors	Allergan, Inc.
2010319727	Polysaccharide gel formulation having multi-stage bioactive agent delivery	Allergan, Inc.
2009257692	Methods of treating alpha adrenergic mediated conditions	Allergan, Inc.
2009267115	Fillable prosthetic implant with gel-like properties	Allergan, Inc.
2010315051	Ophthalmic formulations containing substituted gamma lactams and methods for use thereof	Allergan, Inc.
2010314990	Compositions and methods for stimulating hair growth	Allergan, Inc.
2009266859	Compositions and methods for tissue filling and regeneration	Allergan, Inc.
2009267111	Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity	Allergan, Inc.
2009268549	Cyclosporin derivatives for treating ocular and dermal diseases and conditions	Allergan, Inc.
2011200463	Macromolecule-containing sustained release intraocular implants and related methods	Allergan, Inc.
2009271133	Implantable pump system with calibration	Allergan, Inc.

Number	Title	Owner
2009271168	Method for treating atrophic age related macular degeneration	Allergan, Inc.
2011200507	Piperidinyl prostaglandin E analogs	Allergan, Inc.
2011200584	Ophthalmic compositions and methods for treating ophthalmic conditions	Allergan, Inc.
2009281945	Soft filled prosthesis shell with discrete fixation surfaces	Allergan, Inc.
2009282017	Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof	Allergan, Inc.
2009282189	Therapeutic compounds	Allergan, Inc.
2009282389	Soft filled prosthesis shell with discrete fixation surfaces	Allergan, Inc.
2009282576	Self-sealing shell for inflatable prostheses	Allergan, Inc.
2009282577	Self-sealing shell for inflatable prostheses	Allergan, Inc.
2009282661	Therapeutic substituted pyrroles	Allergan, Inc.
2011201107	Medicaments and methods for treating headache	Allergan, Inc.
2009305625	Prosthetic implant shell	Allergan, Inc.
2011202060	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions	Allergan, Inc.
2009305623	Prosthetic implant shell	Allergan, Inc.
2009307816	Drug delivery systems and methods for treating neovascularization	Allergan, Inc.
2009308017	Ophthalmic compositions useful for improving visual acuity	Allergan, Inc.
2009320143	Clinical assessment scales and methods	Allergan, Inc.
2011202200	Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision	Allergan, Inc.
2011202219	Fusion proteins (61) 2005311086	Health Protection Agency ; Allergan Inc.
2011202225	Non-cytotoxic protein conjugates (61) 2005311098	Health Protection Agency ; Allergan, Inc.
2009317932	Early treatment and prevention of increased muscle tonicity	Allergan, Inc.
2009322463	Injection device	Allergan, Inc.
2009314266	Biodegradable alpha-2 adrenergic agonist polymeric implants	Allergan, Inc.
2009316547	System and method for molding soft fluid-filled implant shells	Allergan, Inc.
2009322578	Kit and composition for eyelash growth	Allergan, Inc.
2009330647	A prosthetic device and method of manufacturing the same	Allergan, Inc.
2011202937	8-azaprostaglandin analogs as agents for lowering intraocular pressure	Allergan, Inc.
2009333620	N- (1-phenyl-2-arylethyl)-4,5-dihydro-3H-pyrrol-2-amine compounds as subtype selective modulators of alpha2B or alpha2B and alpha2C adrenoceptors	Allergan, Inc.
2009339292	Clostridial toxin pharmaceutical compositions	Allergan, Inc.

Terms and Conditions

General

The information provided in this report is not in the nature of legal or other professional advice.

The information provided in this report is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals regarding any information in this report.

Patents, patent applications, trademarks and trademark applications shown as lapsed or ceased may be restored at a later date.

Disclaimer of warranty and limitation of liability

Neither IPMonitor, its affiliates nor any of their respective employees, agents, third party content providers or licensors warrant that the information contained in this report is error free; nor do they make any warranty as to the accuracy, reliability or content of any information in this report.

This report is provided on an "as is" basis; to the maximum extent permitted by law, IPMonitor disclaims all representations and warranties, express or implied, with respect to any information contained in this report. In addition, IPMonitor does not represent or warrant that the information contained in this report is accurate, complete or current.

This disclaimer of liability applies to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action.

Copyright

The content of this report may be protected by copyright laws and treaties around the world and all rights relating to the same are reserved. Any paper or digital copies of this report are not to be modified or any illustrations or any graphics used separately from any accompanying text.

Arbitration

Any dispute or difference whatsoever arising out of or in connection with this report shall be submitted to arbitration in accordance with, and subject to, The Institute of Arbitrators & Mediators Australia Rules for the Conduct of Commercial Arbitrations.

IPMonitor reserves the right to update the Terms and Conditions at any time without notice. Please see the full Terms and Conditions at www.IPMonitor.com.au/trademarks/info/terms